The role of EGFR inhibition in HPV-associated oropharyngeal cancer vs. HPV-negative head and neck cancer remains controversial and may differ depending on whether given as monotherapy or combined with chemotherapy or radiotherapy. The gene discussed is EGFR; the disease is oropharynx cancer.